Pulmonary Thromboembolic Events in COVID-19

In a recently published systematic literature review, members of PVRI Innovative Drug Development Initiative’s Sequelae of COVID-19 Workstream, including Fluidda CEO Jan De Backer and CSO Ben Lavon, sought to summarize the vast body of research into pulmonary vascular manifestations and sequelae of COVID-19. The article, which will appear in the journal Pulmonary Circulation, surveyed the reported incidence of pulmonary embolism (PE), microthrombi, and other thromboembolic complications during the first 2 years of the ongoing pandemic.

Based on the results of the literature review, the authors remarked on the difficulties of detecting and characterizing pulmonary vascular events and complications, and emphasize the need for additional research into novel imaging and other modalities to better diagnose, phenotype, and treat patients during and after COVID-19.

You can read the full manuscript here:


Categorised in: / August 18, 2022 12:27 pm / Published by

Tags: ,